Stockscreener 앱 받기
1.74
1.69%
-0.03
시장 영업 전:
1.83
0.09
+5.17%
전일 마감가:
$1.77
열려 있는:
$1.76
하루 거래량:
4.80M
Relative Volume:
0.62
시가총액:
$570.54M
수익:
$4.41M
순이익/손실:
$-67.85M
주가수익비율:
-7.7059
EPS:
-0.2258
순현금흐름:
$-57.15M
1주 성능:
-3.87%
1개월 성능:
+8.07%
6개월 성능:
-1.14%
1년 성능:
+168.19%
1일 변동 폭
$1.68
$1.79
1주일 범위
$1.68
$1.90
52주 변동 폭
$0.57
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.74 | 570.54M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial - MyChesCo
Ocugen Inc. stock falls Tuesday, underperforms market - marketwatch.com
Pharma News: Will Ocugen Inc stock recover after earningsTreasury Yields & Community Consensus Picks - baoquankhu1.vn
Ocugen (OCGN) up 2.9% since last earnings report: Can it continue? - MSN
Ocugen Inc. stock falls Monday, underperforms market - marketwatch.com
Aug Macro: Is Ocugen Inc undervalued by DCF analysisWeekly Stock Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Q1 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - finance.yahoo.com
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Assessing Ocugen (OCGN) Valuation After Strong One Year Share Price Momentum - Sahm
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - investing.com
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - bitget.com
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - Investing.com South Africa
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - marketwatch.com
$Ocugen (OCGN.US)$ - Moomoo
Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | Ocugen, Inc. - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - gurufocus.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - marketscreener.com
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - ChartMill
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc. stock rises Tuesday, outperforms market - marketwatch.com
OCGN PE Ratio & Valuation, Is OCGN Overvalued - Intellectia AI
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data - insidermonkey.com
Ocugen, Inc. (NASDAQ:OCGN) Q3 2025 Earnings Call Transcript - MSN
Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts - Traders Union
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Risk Recap: Is Ocugen Inc undervalued by DCF analysisMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations - Yahoo Finance
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood - Insider Monkey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen - Stock Titan
Can Ocugen succeed where other gene therapy makers have struggled? - Pharma Voice
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies - TipRanks
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.75%
자본화:
|
볼륨(24시간):